ストックスクリーナーアプリを入手
22.99
1.79%
-0.35
前日終値:
$23.34
開ける：
$23.23
24時間の取引高:
27,769
Relative Volume:
0.20
時価総額：
$453.82M
収益：
$71.10M
当期純損益:
$-6.38M
株価収益率:
-19.14
EPS:
-1.2009
ネットキャッシュフロー:
$-39.84M
1週間 パフォーマンス:
+0.89%
1か月 パフォーマンス:
-19.99%
6か月 パフォーマンス:
-31.57%
1年 パフォーマンス:
+32.97%
1日の値動き範囲:
$22.58
$23.42
1週間の範囲:
$21.80
$24.15
52週間の値動き範囲:
$16.50
$39.70
Assembly Biosciences Inc Stock (ASMB) Company Profile
名前
Assembly Biosciences Inc
セクター
電話
(833) 409-4583
住所
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
22.90 | 462.53M | 71.10M | -6.38M | -39.84M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
449.32 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.56 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.10 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.06 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.83 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-24 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-08-18 | 再開されました | H.C. Wainwright | Buy |
| 2025-03-25 | 開始されました | Guggenheim | Buy |
| 2024-09-20 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-13 | 開始されました | H.C. Wainwright | Neutral |
| 2021-09-02 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-03-23 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-06 | ダウングレード | Jefferies | Buy → Hold |
| 2020-10-19 | 開始されました | Truist | Buy |
| 2019-10-16 | 開始されました | Mizuho | Buy |
| 2018-11-19 | 開始されました | Leerink Partners | Outperform |
| 2018-10-08 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-08-08 | 開始されました | Robert W. Baird | Outperform |
| 2018-04-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Neutral |
| 2017-11-08 | 開始されました | Jefferies | Buy |
| 2017-05-30 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Assembly Biosciences Inc (ASMB) 最新ニュース
ASMB Maintained by Mizuho -- Price Target Raised to $45 - GuruFocus
Assembly Biosciences eyes Gilead HSV plan as ABI-6250 liver pipeline expands - MSN
ASMB SEC FilingsAssembly Bioscie 10-K, 10-Q, 8-K Forms - Stock Titan
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead - MarketBeat
(ASMB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Assembly Biosciences Expands Equity Plans, Reelects Board - TipRanks
Assembly Biosciences (ASMB) CMO awarded 14,000-share RSU-based stock grant - Stock Titan
Assembly Biosciences (ASMB) CMO awarded 14,000 restricted stock units - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) awards 8,000 stock options to director McHutchison - Stock Titan
Assembly Biosciences (ASMB) director receives grant of 8,000 stock options - Stock Titan
Director at Assembly Biosciences (ASMB) receives grant of 8,000 stock options - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) director receives 8,000 stock options grant - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) director receives grant of 8,000 stock options - Stock Titan
Director at Assembly Biosciences (NASDAQ: ASMB) receives 8,000 options - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) PFO awarded 3,500 RSUs - Stock Titan
Assembly Biosciences (ASMB) CSO granted 14,000 RSUs tied to plan amendment - Stock Titan
Assembly Biosciences (ASMB) CEO receives 50,750 RSUs in equity grant - Stock Titan
Assembly Biosciences (ASMB) shareholders back directors, equity plan and ESPP share hikes - Stock Titan
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands - Yahoo Finance
Assembly Biosciences synthesizes new anti-cytomegalovirus agents - BioWorld News
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Biosciences Inc. - GuruFocus
Assembly Biosciences Announces Upcoming Investor Conference Presentations - The Manila Times
ASMB Reiterated by Guggenheim -- Price Target Maintained at $43 - GuruFocus
Biotech Assembly Bio set for June Jefferies, Goldman investor chats - Stock Titan
Assembly Biosciences (ASMB) Holds Steady Near Resistance as Biotech Sector WatchesSector ETF Flow - The Legal Advocate
How (ASMB) Movements Inform Risk Allocation Models - Stock Traders Daily
Gilead boosts Assembly Biosciences (NASDAQ: ASMB) ownership to 25.1% of shares - Stock Titan
Gilead adds Assembly Biosciences (ASMB) shares through new stock grant - Stock Titan
Assembly Biosciences (ASMB) Declines 4.7% as Stock Tests Key Support Near $26PCR Moving Average - newsline.com
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - The Manila Times
Assembly Biosciences closes $115 million stock offering - Investing.com UK
Assembly Biosciences closes $115 million stock offering By Investing.com - Investing.com South Africa
Assembly Biosciences Completes Significant Equity Offering Financing - TipRanks
Assembly Biosciences (ASMB) completes $115M stock and pre-funded warrant sale - Stock Titan
Assembly Bio raises $115M for viral and liver drug clinical work - Stock Titan
Assembly Biosciences Surges 6.9% as Buyers Defend Key Support Level (ASMB)High Dividend Factor - The Legal Advocate
Assembly Biosciences prices $100M equity offering - MSN
Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday - Sahm
Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC - TradingView
Assembly Biosciences (NASDAQ: ASMB) raises ~$93M; 3.36M shares, 415K pre-funded warrants - Stock Titan
Assembly Biosciences (ASMB) Expands Clinical Focus on Liver Dise - GuruFocus
Assembly Biosciences (ASMB) Prices $100M Offering to Support Cli - GuruFocus
Assembly Biosciences (NASDAQ: ASMB) launches stock and pre-funded warrant offering - Stock Titan
Assembly Biosciences prices $100 million stock offering at $26.50 - Investing.com UK
Assembly Biosciences Expands ABI-6250 Clinical Development to Target Cholestatic Liver Diseases Including PBC and PSC - Minichart
Assembly Biosciences expands ABI-6250 development to liver diseases By Investing.com - Investing.com Nigeria
Assembly Biosciences expands ABI-6250 development to liver diseases - Investing.com UK
Assembly Biosciences prices $100 million stock offering at $26.50 By Investing.com - Investing.com South Africa
Assembly Biosciences prices $100 million offering - The Pharma Letter
Assembly Biosciences Inc (ASMB) 財務データ
収益
当期純利益
現金流量
EPS
2.40%
0.80%
大文字化:
|
ボリューム (24 時間):